Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent

Renuka T.R. Menon, Tali Feferman, Revital Aricha, Miriam C. Souroujon, Sara Fuchs

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

ملخص

Myasthenia gravis (MG) is frequently treated by corticosteroids such as methylprednisolone. However, continuous treatment with steroids often results in adverse effects. In the present study we evaluated the therapeutic potential of a combination of suboptimal doses of methylprednisolone (Solumedrol) and Pentoxifylline (PTX), a general phosphodiesterase (PDE) inhibitor, in rat experimental autoimmune MG (EAMG). This combined treatment resulted in a pronounced suppressive effect on EAMG and was by far more effective than each of the drugs administered separately at these low doses. The suppressive effect on EAMG was accompanied by decreased humoral and cellular responses to AChR as well as down-regulated mRNA expression levels of Th1 cytokines and IL-10 in lymph node cells and of PDE-4 and cathepsin-l in the muscle. This study demonstrates the potential of PTX as a steroid-sparing agent in the management of myasthenia gravis.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)128-135
عدد الصفحات8
دوريةJournal of Neuroimmunology
مستوى الصوت201-202
رقم الإصدارC
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - 15 سبتمبر 2008

ملاحظة ببليوغرافية

Funding Information:
This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The Association Francaise Contre les Myopathies (AFM) and The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833).

بصمة

أدرس بدقة موضوعات البحث “Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا